A pathway-based analysis of urinary arsenic metabolites and skin lesions

Molly L. Kile, Elaine Hoffman, Ema G. Rodrigues, Carrie V. Breton, Quazi Quamruzzaman, Mahmuder Rahman, Golam Mahiuddin, Yu Mei Hsueh, David C. Christiani

研究成果: 雜誌貢獻文章

44 引文 (Scopus)

摘要

Inorganic arsenic is metabolized to monomethylarsonic acid (MMA) and dimethylarsinic acid (DMA). Limited evidence suggests that the ability to fully metabolize arsenic into DMA influences susceptibility to disease. To determine whether percentage of MMA was predictive of disease, the authors used data from a case-control study conducted in Bangladesh (2001-2003). Persons who were diagnosed with keratosis, melanosis, Bowen's disease, or squamous cell carcinoma were matched on age, sex, and village to persons without these conditions. This analysis was restricted to persons who had no missing data on covariates (859 cases, 868 controls). A path analysis was used to evaluate simultaneously the association between the percentage of all urinary arsenic metabolites and the odds of skin lesions using PROC CALIS in SAS, version 9.1 (SAS Institute, Inc., Cary, North Carolina) and Mplus, version 6.1 (Muthén & Muthén, Los Angeles, California). The odds of skin lesions were significantly associated with log10 percentage of MMA (adjusted odds ratio (ORadj) = 1.56, 95% confidence interval (CI): 1.15, 2.12) but not log10 percentage of inorganic arsenic (ORadj = 1.06, 95% CI: 0.75, 1.50) or log10 percentage of DMA (ORadj = 1.07, 95% CI: 0.33, 3.46). This novel analysis confirmed that persons who excrete a higher proportion of MMA have a greater risk of skin lesions after data are adequately controlled for urinary arsenic metabolites, current arsenic exposure, and other risk factors.

原文英語
頁(從 - 到)778-786
頁數9
期刊American Journal of Epidemiology
173
發行號7
DOIs
出版狀態已發佈 - 四月 1 2011

指紋

Arsenic
Cacodylic Acid
Skin
Confidence Intervals
Bowen's Disease
Keratosis
Melanosis
Bangladesh
Los Angeles
Disease Susceptibility
Case-Control Studies
Squamous Cell Carcinoma
Odds Ratio
monomethylarsonic acid

ASJC Scopus subject areas

  • Epidemiology

引用此文

Kile, M. L., Hoffman, E., Rodrigues, E. G., Breton, C. V., Quamruzzaman, Q., Rahman, M., ... Christiani, D. C. (2011). A pathway-based analysis of urinary arsenic metabolites and skin lesions. American Journal of Epidemiology, 173(7), 778-786. https://doi.org/10.1093/aje/kwq427

A pathway-based analysis of urinary arsenic metabolites and skin lesions. / Kile, Molly L.; Hoffman, Elaine; Rodrigues, Ema G.; Breton, Carrie V.; Quamruzzaman, Quazi; Rahman, Mahmuder; Mahiuddin, Golam; Hsueh, Yu Mei; Christiani, David C.

於: American Journal of Epidemiology, 卷 173, 編號 7, 01.04.2011, p. 778-786.

研究成果: 雜誌貢獻文章

Kile, ML, Hoffman, E, Rodrigues, EG, Breton, CV, Quamruzzaman, Q, Rahman, M, Mahiuddin, G, Hsueh, YM & Christiani, DC 2011, 'A pathway-based analysis of urinary arsenic metabolites and skin lesions', American Journal of Epidemiology, 卷 173, 編號 7, 頁 778-786. https://doi.org/10.1093/aje/kwq427
Kile ML, Hoffman E, Rodrigues EG, Breton CV, Quamruzzaman Q, Rahman M 等. A pathway-based analysis of urinary arsenic metabolites and skin lesions. American Journal of Epidemiology. 2011 4月 1;173(7):778-786. https://doi.org/10.1093/aje/kwq427
Kile, Molly L. ; Hoffman, Elaine ; Rodrigues, Ema G. ; Breton, Carrie V. ; Quamruzzaman, Quazi ; Rahman, Mahmuder ; Mahiuddin, Golam ; Hsueh, Yu Mei ; Christiani, David C. / A pathway-based analysis of urinary arsenic metabolites and skin lesions. 於: American Journal of Epidemiology. 2011 ; 卷 173, 編號 7. 頁 778-786.
@article{51e67bc647b345589f8b42f0fb97ec20,
title = "A pathway-based analysis of urinary arsenic metabolites and skin lesions",
abstract = "Inorganic arsenic is metabolized to monomethylarsonic acid (MMA) and dimethylarsinic acid (DMA). Limited evidence suggests that the ability to fully metabolize arsenic into DMA influences susceptibility to disease. To determine whether percentage of MMA was predictive of disease, the authors used data from a case-control study conducted in Bangladesh (2001-2003). Persons who were diagnosed with keratosis, melanosis, Bowen's disease, or squamous cell carcinoma were matched on age, sex, and village to persons without these conditions. This analysis was restricted to persons who had no missing data on covariates (859 cases, 868 controls). A path analysis was used to evaluate simultaneously the association between the percentage of all urinary arsenic metabolites and the odds of skin lesions using PROC CALIS in SAS, version 9.1 (SAS Institute, Inc., Cary, North Carolina) and Mplus, version 6.1 (Muth{\'e}n & Muth{\'e}n, Los Angeles, California). The odds of skin lesions were significantly associated with log10 percentage of MMA (adjusted odds ratio (ORadj) = 1.56, 95{\%} confidence interval (CI): 1.15, 2.12) but not log10 percentage of inorganic arsenic (ORadj = 1.06, 95{\%} CI: 0.75, 1.50) or log10 percentage of DMA (ORadj = 1.07, 95{\%} CI: 0.33, 3.46). This novel analysis confirmed that persons who excrete a higher proportion of MMA have a greater risk of skin lesions after data are adequately controlled for urinary arsenic metabolites, current arsenic exposure, and other risk factors.",
keywords = "arsenic, Bangladesh, methylation, organometallic compounds, skin lesions, water",
author = "Kile, {Molly L.} and Elaine Hoffman and Rodrigues, {Ema G.} and Breton, {Carrie V.} and Quazi Quamruzzaman and Mahmuder Rahman and Golam Mahiuddin and Hsueh, {Yu Mei} and Christiani, {David C.}",
year = "2011",
month = "4",
day = "1",
doi = "10.1093/aje/kwq427",
language = "English",
volume = "173",
pages = "778--786",
journal = "American Journal of Epidemiology",
issn = "0002-9262",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - A pathway-based analysis of urinary arsenic metabolites and skin lesions

AU - Kile, Molly L.

AU - Hoffman, Elaine

AU - Rodrigues, Ema G.

AU - Breton, Carrie V.

AU - Quamruzzaman, Quazi

AU - Rahman, Mahmuder

AU - Mahiuddin, Golam

AU - Hsueh, Yu Mei

AU - Christiani, David C.

PY - 2011/4/1

Y1 - 2011/4/1

N2 - Inorganic arsenic is metabolized to monomethylarsonic acid (MMA) and dimethylarsinic acid (DMA). Limited evidence suggests that the ability to fully metabolize arsenic into DMA influences susceptibility to disease. To determine whether percentage of MMA was predictive of disease, the authors used data from a case-control study conducted in Bangladesh (2001-2003). Persons who were diagnosed with keratosis, melanosis, Bowen's disease, or squamous cell carcinoma were matched on age, sex, and village to persons without these conditions. This analysis was restricted to persons who had no missing data on covariates (859 cases, 868 controls). A path analysis was used to evaluate simultaneously the association between the percentage of all urinary arsenic metabolites and the odds of skin lesions using PROC CALIS in SAS, version 9.1 (SAS Institute, Inc., Cary, North Carolina) and Mplus, version 6.1 (Muthén & Muthén, Los Angeles, California). The odds of skin lesions were significantly associated with log10 percentage of MMA (adjusted odds ratio (ORadj) = 1.56, 95% confidence interval (CI): 1.15, 2.12) but not log10 percentage of inorganic arsenic (ORadj = 1.06, 95% CI: 0.75, 1.50) or log10 percentage of DMA (ORadj = 1.07, 95% CI: 0.33, 3.46). This novel analysis confirmed that persons who excrete a higher proportion of MMA have a greater risk of skin lesions after data are adequately controlled for urinary arsenic metabolites, current arsenic exposure, and other risk factors.

AB - Inorganic arsenic is metabolized to monomethylarsonic acid (MMA) and dimethylarsinic acid (DMA). Limited evidence suggests that the ability to fully metabolize arsenic into DMA influences susceptibility to disease. To determine whether percentage of MMA was predictive of disease, the authors used data from a case-control study conducted in Bangladesh (2001-2003). Persons who were diagnosed with keratosis, melanosis, Bowen's disease, or squamous cell carcinoma were matched on age, sex, and village to persons without these conditions. This analysis was restricted to persons who had no missing data on covariates (859 cases, 868 controls). A path analysis was used to evaluate simultaneously the association between the percentage of all urinary arsenic metabolites and the odds of skin lesions using PROC CALIS in SAS, version 9.1 (SAS Institute, Inc., Cary, North Carolina) and Mplus, version 6.1 (Muthén & Muthén, Los Angeles, California). The odds of skin lesions were significantly associated with log10 percentage of MMA (adjusted odds ratio (ORadj) = 1.56, 95% confidence interval (CI): 1.15, 2.12) but not log10 percentage of inorganic arsenic (ORadj = 1.06, 95% CI: 0.75, 1.50) or log10 percentage of DMA (ORadj = 1.07, 95% CI: 0.33, 3.46). This novel analysis confirmed that persons who excrete a higher proportion of MMA have a greater risk of skin lesions after data are adequately controlled for urinary arsenic metabolites, current arsenic exposure, and other risk factors.

KW - arsenic

KW - Bangladesh

KW - methylation

KW - organometallic compounds

KW - skin lesions

KW - water

UR - http://www.scopus.com/inward/record.url?scp=79953867214&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953867214&partnerID=8YFLogxK

U2 - 10.1093/aje/kwq427

DO - 10.1093/aje/kwq427

M3 - Article

C2 - 21378128

AN - SCOPUS:79953867214

VL - 173

SP - 778

EP - 786

JO - American Journal of Epidemiology

JF - American Journal of Epidemiology

SN - 0002-9262

IS - 7

ER -